Repair Biotechnologies
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$500k | Seed | ||
N/A | N/A | Convertible | |
N/A | N/A | Seed | |
* | N/A | $8.4m | Early VC |
Total Funding | AUD13.8m |
Related Content
Recent News about Repair Biotechnologies
EditRepair Biotechnologies, founded in 2018 by Reason and Bill Cherman, is a biotechnology company focused on developing therapies to combat age-related diseases and extend human healthspan. The company operates in the longevity sector, aiming to address the root causes of aging through innovative medical treatments. Repair Biotechnologies targets conditions such as atherosclerosis and thymus atrophy, which are significant contributors to aging and related diseases. The company serves a broad market that includes healthcare providers, research institutions, and potentially aging individuals seeking to improve their quality of life.
Repair Biotechnologies' business model revolves around research and development, clinical trials, and eventual commercialization of their therapies. Revenue is generated through partnerships, grants, and future sales of approved treatments.
Keywords: longevity, healthspan, aging, atherosclerosis, thymus atrophy, biotechnology, therapies, clinical trials, healthcare, innovation.